- Home
- NEGG vs AVIR Comparison
NEGG vs AVIR Comparison
Compare NEGG & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- AVIR
- Stock Information
- Founded
- NEGG 2001
- AVIR 2012
- Country
- NEGG United States
- AVIR United States
- Employees
- NEGG N/A
- AVIR N/A
- Industry
- NEGG Other Specialty Stores
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- NEGG Consumer Discretionary
- AVIR Health Care
- Exchange
- NEGG Nasdaq
- AVIR Nasdaq
- Market Cap
- NEGG 293.6M
- AVIR 276.9M
- IPO Year
- NEGG 2010
- AVIR 2020
- Fundamental
- Price
- NEGG $0.63
- AVIR $3.22
- Analyst Decision
- NEGG
- AVIR Hold
- Analyst Count
- NEGG 0
- AVIR 1
- Target Price
- NEGG N/A
- AVIR $6.88
- AVG Volume (30 Days)
- NEGG 558.6K
- AVIR 175.5K
- Earning Date
- NEGG 11-22-2024
- AVIR 11-07-2024
- Dividend Yield
- NEGG N/A
- AVIR N/A
- EPS Growth
- NEGG N/A
- AVIR N/A
- EPS
- NEGG N/A
- AVIR N/A
- Revenue
- NEGG $1,391,833,000.00
- AVIR N/A
- Revenue This Year
- NEGG $6.01
- AVIR N/A
- Revenue Next Year
- NEGG N/A
- AVIR N/A
- P/E Ratio
- NEGG N/A
- AVIR N/A
- Revenue Growth
- NEGG N/A
- AVIR N/A
- 52 Week Low
- NEGG $0.58
- AVIR $2.77
- 52 Week High
- NEGG $2.15
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- NEGG 44.36
- AVIR 39.98
- Support Level
- NEGG $0.62
- AVIR $3.32
- Resistance Level
- NEGG $0.68
- AVIR $3.48
- Average True Range (ATR)
- NEGG 0.06
- AVIR 0.14
- MACD
- NEGG 0.00
- AVIR -0.01
- Stochastic Oscillator
- NEGG 21.23
- AVIR 9.09
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).